Blinatumomab - CISMeF

Preferred Label : Blinatumomab;

NCIt synonyms : Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody; Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103; Anti-CD19 Anti-CD3 Bispecific Monoclonal Antibody;

NCIt definition : A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.;

UNII : 4FR53SIF3A;

CAS number : 853426-35-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 853426-35-4 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Blincyto;

Molecule name : MEDI-538; MT-103; AMG 103;

Codes from synonyms : 74;

Details

Origin ID

C62528;

UMLS CUI

C3853839;

Automatic exact mappings (from CISMeF team)
- Blinatumomab [ICD-11 Extension code]
CISMeF manual mappings
- Blinatumomab (substance) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Blinatumomab [Substance BNPC]
- blinatumomab [MeSH concept]
- blinatumomab [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing blinatumomab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Blinatumomab [Substance BNPC]
- Blinatumomab (substance) [SNOMED CT concept]
- Product containing blinatumomab (medicinal product) [SNOMED CT concept]
- blinatumomab [ATC Code]
- blinatumomab [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- blinatumomab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD19 [NCIt concept]
is_component_of_chemotherapy_regimen
- Blinatumomab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients